Literature DB >> 7117919

Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin.

M Hellgren, L Tengborn, U Abildgaard.   

Abstract

The incidence of thromboembolic complications (TE) during pregnancy in women with congenital antithrombin III (AT) deficiency has retrospectively been estimated to be about 70%. 8 women with congenital AT deficiency were studied during 9 pregnancies. Subcutaneous or intravenous heparin in doses to prolong the activated partial thromboplastin time (APTT) was given during pregnancy as prophylaxis or therapeutic treatment. During delivery and abortion the AT level was brought to normal by infusion of AT concentrate and the heparin was reduced or withdrawn. Four pregnancies were uncomplicated with regard to TE and resulted in 4 healthy children. Five pregnancies were terminated by induced or spontaneous abortion. 1 woman had TE during heparin prophylaxis and 2 women had TE before the prophylaxis was started. 1 of the latter suffered from a new TE during continued heparing treatment. Insufficient prolongation of APTT was registered at the time of TE in both women with TE during heparin treatment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7117919     DOI: 10.1159/000299460

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  13 in total

1.  The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: second revision. BCSH Haemostasis and Thrombosis Task Force.

Authors:  B T Colvin; T W Barrowcliffe
Journal:  J Clin Pathol       Date:  1993-02       Impact factor: 3.411

Review 2.  Familial venous thrombosis.

Authors:  J H Winter; A S Douglas
Journal:  Postgrad Med J       Date:  1983-11       Impact factor: 2.401

Review 3.  Thrombophilia in pregnancy.

Authors:  I D Walker
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

Review 4.  Emerging concepts in the diagnosis and management of venous thromboembolism during pregnancy.

Authors:  M M Burns
Journal:  J Thromb Thrombolysis       Date:  2000-08       Impact factor: 2.300

5.  Guidelines on the prevention, investigation and management of thrombosis associated with pregnancy. Maternal and Neonatal haemostasis Working Party of the Haemostasis and Thrombosis Task.

Authors: 
Journal:  J Clin Pathol       Date:  1993-06       Impact factor: 3.411

6.  Heparin 1986. Indications and effective use.

Authors:  P Ockelford
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

Review 7.  Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options.

Authors:  Peter S Maclean; R Campbell Tait
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency.

Authors:  Andra H James; Barbara A Konkle; Kenneth A Bauer
Journal:  Int J Womens Health       Date:  2013-05-03

9.  Antithrombin III in patients admitted to intensive care units: a multicenter observational study.

Authors:  Andrea Messori; Franca Vacca; Monica Vaiani; Sabrina Trippoli
Journal:  Crit Care       Date:  2002-07-24       Impact factor: 9.097

10.  Use of recombinant human antithrombin concentrate in pregnancy.

Authors:  Lisa M Baumann Kreuziger; Tracy L Prosen; Mark T Reding
Journal:  Int J Womens Health       Date:  2013-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.